Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment

Tommy A A Broeders1, Maureen van Dam1, Giuseppe Pontillo1

  • 1From the MS Center Amsterdam (T.A.A.B., M.v.D., V.R., L.D., Y.D.v.d.W., C.H.V., M.M.S.), Anatomy & Neurosciences, and MS Center Amsterdam (G.P., F.B.), Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (G.P., F.B.), University College London, United Kingdom; Departments of Advanced Biomedical Sciences and Electrical Engineering and Information Technology (G.P.), University of Naples "Federico II," Italy; MS Center Amsterdam (J.K.), Neurology, and MS Center Amsterdam (C.H.V.), Psychiatry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc; Amsterdam Public Health (C.H.V.), Mental Health Program; and GGZ inGeest Mental Health Care (C.H.V.), Amsterdam, the Netherlands.

Neurology
|October 11, 2024
PubMed
Summary

Cognitively impaired multiple sclerosis (MS) patients show less frequent brain network state transitions due to higher energy costs. Specifically, shifts from the default mode network to the visual network were significantly impacted, affecting cognitive function.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
65
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106